Biotech - Excellence from Hesse: BioSpring's CEO Dr. Sylvia Wojczewski for talks in Brussels

Brussels/Frankfurt am Main, 24.09.2024. " Biotechnology as a driver of innovation - success factors for a strong location" was the leitmotif of an information and discussion event at which high-ranking representatives from politics and business met at the Representation of the State of Hesse to the European Union in Brussels.

In her keynote speech at the start of the meeting, Dr. Sylvia Wojczewski, CEO and co-owner of BioSpring Gesellschaft für Biotechnologie mbH, named the necessary framework conditions for the successful development of the industry and underlined its enormous potential for value creation. In particular, she referred to the success story of her own company. Dr. Sylvia Wojczewski and Dr. Hüseyin Aygün founded BioSpring GmbH in 1997, and today the company employs over 650 people.

The event in Brussels took place at the invitation of the Hessian Minister for European Affairs Manfred Pentz (CDU) and the Initiative Gesundheitsindustrie Hessen. BioSpring provided support with the planning and content of the event.

As a technology of the future, medical biotechnology plays a key role in the healthcare industry in Hesse and Europe and thus for a strong business location. Novel drugs such as nucleic acid therapeutics and in particular so-called oligonucleotides - short sections of synthetic RNA and DNA - are of particular importance: they combat the causes of disease and are highly effective. The therapeutic and economic potential is correspondingly enormous.

In the subsequent panel discussion, Sylvia Wojczewski represented the Hessian biotechnology companies. She emphasized the importance of creating the right conditions, in particular through investment incentives, to ensure both research and development and the production of complex drugs in the state and to further increase future value creation.

The international competitiveness of the European biotechnology industry is particularly dependent on the external framework. The European Union has set ambitious goals, including the planned "Biotech Act". Now it is time to follow up with action.

BioSpring is one of the world's leading manufacturers of active ingredients for synthetic nucleic acids and supplies renowned international biotech and pharmaceutical companies. BioSpring is the global market leader in active ingredients for genome editing. This technology has the potential to completely cure previously incurable diseases instead of just combating symptoms as was previously the case with conventional therapies.

BioSpring produces exclusively in the Rhine-Main region and is currently planning the construction of new industrial-scale production facilities in Offenbach am Main. The aim is to create up to 1,500 new jobs in the region in the long term.